Clovis Oncology CLVS announced today updated findings from the
Phase I portion of its ongoing Phase I/II clinical study of CO-1686, the
Company's novel, oral, targeted covalent (irreversible) inhibitor of
mutant forms of the epidermal growth factor receptor (EGFR) for the
treatment of non-small cell lung cancer (NSCLC) in patients with initial
activating EGFR mutations as well as the dominant resistance mutation
T790M. Interim results from the Phase I dose-escalation portion of this
Phase I/II study are being presented today in an oral presentation by
Professor Jean-Charles Soria at the IASLC 15th World
Conference on Lung Cancer in Sydney.
Six RECIST partial responses have been observed to date in nine
evaluable T790M positive patients dosed
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in